{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:02:45Z","timestamp":1774947765826,"version":"3.50.1"},"reference-count":33,"publisher":"Tech Science Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJU"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/cju.2025.066700","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T08:54:42Z","timestamp":1754556882000},"page":"243-254","source":"Crossref","is-referenced-by-count":4,"title":["National survey of radiotherapy and androgen deprivation therapy strategies with PSMA-PET\/CT integration in intermediate-risk prostate cancer: TROD 09-007 study"],"prefix":"10.32604","volume":"32","author":[{"given":"Aysenur","family":"Elmali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birhan","family":"Demirhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caglayan Selenge Beduk","family":"Esen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pervin","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Onal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, Version 4. 2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2012.07.2374","article-title":"Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy","volume":"85","author":"Zumsteg","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1470-2045(15)00222-3","article-title":"Expanding global access to radiotherapy","volume":"16","author":"Atun","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG, 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijrobp.2025.01.022","article-title":"The benefit of short-term androgen deprivation therapy with radiation therapy for intermediate-risk prostate cancer","volume":"122","author":"Patel","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.eururo.2024.08.032","article-title":"Hypofractionated dose escalation radiotherapy for high-risk prostate cancer: the survival analysis of the prostate cancer study-5 (PCS-5), a GROUQ-led phase III trial","volume":"87","author":"Niazi","year":"2025","journal-title":"Eur Urol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial","volume":"143","author":"Nabid","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pros.24693","article-title":"The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer","volume":"84","author":"Onal","year":"2024","journal-title":"Prostate"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1200\/JCO.2010.29.8091","article-title":"Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer","volume":"28","author":"Alibhai","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2024.05.026","article-title":"Variation in androgen deprivation therapy use among men with intermediate-risk prostate cancer: results from a statewide radiation oncology quality consortium","volume":"120","author":"Dykstra","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2020.08.021","article-title":"Role of 68-Ga-PSMA-PET\/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients","volume":"151","author":"Onal","year":"2020","journal-title":"Radiother Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1097\/RLU.0000000000002691","volume":"44","author":"Onal","year":"2019","journal-title":"Clin Nucl Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"ref18","article-title":"The appropriateness of PSMA PET\/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification","author":"Hagens","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref19","first-page":"1208","volume":"395","author":"Hofman","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/pros.24775","volume":"84","author":"Onal","year":"2024","journal-title":"Prostate"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e2015083","DOI":"10.1001\/jamanetworkopen.2020.15083","article-title":"Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: a secondary analysis of the RTOG, 9408 randomized clinical trial","volume":"3","author":"Zumsteg","year":"2020","journal-title":"JAMA Netw Open"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part I: risk stratification, shared decision making, and care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.canrad.2020.03.014","article-title":"Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group","volume":"24","author":"Belkacemi","year":"2020","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.ijrobp.2009.03.034","article-title":"Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy","volume":"76","author":"Nanda","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"ref28","first-page":"1518","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"104","author":"Keating","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","article-title":"Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer","volume":"36","author":"Spratt","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"110618","DOI":"10.1016\/j.radonc.2024.110618","article-title":"Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer","volume":"202","author":"Wang","year":"2025","journal-title":"Radiother Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2024.09.011","article-title":"Impact of gene expression classifier testing on adjuvant treatment following radical prostatectomy: the G-MINOR prospective randomized cluster-crossover trial","volume":"87","author":"Morgan","year":"2025","journal-title":"Eur Urol"},{"key":"ref33","first-page":"1011","article-title":"Association between the decipher genomic classifier and prostate cancer outcome in the real-world setting","volume":"163","author":"Leapman","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["Canadian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/cju\/2025\/TSP_CJU-32-4\/TSP_CJU_66700\/TSP_CJU_66700.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:04:50Z","timestamp":1763345090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/CJU\/v32n4\/63656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/cju.2025.066700","relation":{},"ISSN":["1488-5581"],"issn-type":[{"value":"1488-5581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}